Gilead Slips As Former Bull Turns Bearish On Hep C Business

Shares of Gilead Sciences are sliding after Leerink analyst Geoffrey Porges downgraded the stock to Market Perform, saying he is now "outright bearish" on the company's Hepatitis C virus business.